Patient survival after resection of skeletal metastases and endoprosthetic reconstruction: a nation-wide cohort study in a single oncological institution
, y
19 mar 2025
Acerca de este artículo
Categoría del artículo: Research Article
Publicado en línea: 19 mar 2025
Páginas: 450 - 456
Recibido: 28 oct 2024
Aceptado: 19 dic 2024
DOI: https://doi.org/10.2478/raon-2025-0009
Palabras clave
© 2025 Aljaz Mercun et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Figure 1.

Cox regression analysis of patient survival for the subcohort of 32 patients with metastases, stratified into histopathological groups according to the 2013-SPRING survival prediction model
B | SE | Exp(B) | 95 % CI for Exp(B) | p-value | ||
---|---|---|---|---|---|---|
Lower | Upper | |||||
Age [per year] | 0.039 | 0.037 | 1.040 | 0.967 | 1.119 | 0.293 |
Gender [male = 1] | 0.235 | 0.622 | 1.265 | 0.373 | 4.285 | 0.706 |
Slow-growing-mets (reference) | 0.022 |
|||||
Fast-growing mets | 1.859 | 0.898 | 6.419 | 1.105 | 37.294 | 0.038 |
Moderate-growing mets | 0.436 | 1.014 | 1.547 | 0.212 | 11.289 | 0.667 |
Pathological fx or > 1 mets | -0.683 | 0.725 | 0.505 | 0.122 | 2.093 | 0.346 |
C-reactive protein [mg/L] | 0.018 | 0.008 | 1.018 | 1.003 | 1.034 | 0.021 |
Leukocyte count [109/L] | 0.096 | 0.081 | 1.100 | 0.940 | 1.289 | 0.234 |
Hemoglobin [g/L] | 0.027 | 0.029 | 1.027 | 0.971 | 1.087 | 0.348 |
Thrombocyte count [109/L] | 0.000 | 0.005 | 1.000 | 0.989 | 1.011 | 0.980 |
Demographic characteristics, oncological stage and observed survival of patients stratified according to the histopathological diagnosis according to the 2013-SPRING survival prediction model
Fast-growing metastases | Moderate-growing metastases | Slow-growing metastases | Sarcomas | Non-oncological patients | |
---|---|---|---|---|---|
No. of subjects | 12 | 11 | 9 | 73 | 39 |
Mean age [years] | 63 ± 14 | 65 ± 10 | 64 ± 12 | 42 ± 21 | 53 ± 19 |
Gender [Female/Male] | 6 / 6 | 2 / 9 | 8 / 1 | 39 / 34 | 20 / 19 |
Percentage of patients with pathological fracture or > 1 metastasis | 75% | 73% | 44% | 18% | 0% |
Patients alive 2 years after the operation |
25% | 55% | 88% | 80% | 100% |
Patients alive 5 years after the operation |
10% | 30% | 83% | 69% | 97% |
Implant removed within 2 years after the operation |
0% | 9% | 13% | 9% | 11% |
Implant removed within 5 years after the operation |
10% | 10% | 17% | 18% | 19% |
Cox regression analysis of patient survival for the cohort of 144 patients with tumor endoprosthetic reconstructions, stratified into histopathological groups according to the 2013-SPRING survival prediction model
B | SE | Exp(B) | 95 % CI for Exp(B) | p-value | ||
---|---|---|---|---|---|---|
Lower | Upper | |||||
Age [per year] | 0.021 | 0.010 | 1.021 | 1.002 | 1.041 | 0.031 |
Gender [male = 1] | -0.410 | 0.304 | 0.664 | 0.366 | 1.205 | 0.178 |
Slow-growing-mets (reference) | 0.002 |
|||||
Fast-growing mets | 1.709 | 0.674 | 5.522 | 1.473 | 20.703 | 0.011 |
Moderate-growing mets | 0.853 | 0.703 | 2.347 | 0.592 | 9.308 | 0.225 |
Sarcomas | 0.831 | 0.661 | 2.296 | 0.629 | 8.378 | 0.208 |
Non-oncological patients | -1.315 | 0.964 | 0.269 | 0.041 | 1.776 | 0.173 |
Pathological fx or > 1 mets | 1.032 | 0.350 | 2.809 | 1.414 | 5.587 | 0.003 |